Yuandong Biotech announced that Chengdu Shuode Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for bonatinib tablets approved and issued by the State Drug Administration. This drug is a third-generation BCR-ABL tyrosine kinase inhibitor for leukemia. It is the first generic drug approved according to category 4 chemicals in China. The specification is 15 mg. The marketing license holder and manufacturer are all Chengdu Shuode Pharmaceutical Co., Ltd. The approval of the drug will not have a significant impact on the company's recent performance.

Yuandong Biotech announced that Chengdu Shuode Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for bonatinib tablets approved and issued by the State Drug Administration. This drug is a third-generation BCR-ABL tyrosine kinase inhibitor for leukemia. It is the first generic drug approved according to category 4 chemicals in China. The specification is 15 mg. The marketing license holder and manufacturer are all Chengdu Shuode Pharmaceutical Co., Ltd. The approval of the drug will not have a significant impact on the company's recent performance.